Next Generation Complement Therapeutics Market Size is valued at 6.9 billion in 2022 and is predicted to reach 23.04 billion by the year 2031 at a 14.39% CAGR during the forecast period for 2023-2031.
The complement system is vital in pathogen immunosurveillance, and complement activation is a part of numerous inflammatory diseases. Hence, several pharma companies started focusing on discovering next-generation complement therapeutics to treat different disease conditions.
Major driving factors of the next-generation complement therapeutics market are rising government efforts to develop complement-targeted therapeutics, advancements in technologies, increasing investments by pharma companies to innovate next-generation complement therapeutics products, growing patient population, increasing R&D activities in complement therapeutics, growing prevalence of chronic diseases, and the high need for novel therapeutics to manage normal immune system functioning. Various drug developers prefer adopting next-generation technologies to develop complement-targeted therapeutics for effectively treating immunodeficiency disorders. This adoption is predicted to compel market growth in the upcoming years. However, a large population living with complement deficiency remains undiagnosed, hindering the market growth during the estimated timeframe.
Market Segmentation:
The next-generation complement therapeutics market is segmented into target disease indication, therapeutic area, molecule type, type of therapy, route of administration, and region.
Based On The Target Disease Indication, The Atypical Hemolytic Uremic Syndrome Segment Is A Major Contributor To The Next-Generation Complement Therapeutics Market.
The target disease indication segment comprises Atypical Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, and Neuromyelitis Optica. The Atypical Hemolytic Uremic Syndrome segment is expected to lead the market during the projection period on account of the rising prevalence of the syndrome.
The therapeutic area segment includes cardiovascular, genetic, hematological and vascular, infectious, neurological and neuromuscular disorders. The market is grouped into biologic and small molecules based on the molecule type. The market is classified into monotherapy and combination therapy based on the kind of therapy. Route of administration segment splits into intravenous, oral, and subcutaneous. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
In The Region, The North American Next-Generation Complement Therapeutics Market Holds A Significant Revenue Share.
North America dominated this market in 2022. The presence of a well-established healthcare infrastructure, advantageous reimbursement policies, collaborative partnerships, the introduction of new products, and notable pharmaceutical companies involved in Complement Inhibitors are all contributing factors. Moreover, The Asia-Pacific market is projected to notice substantial growth during the forecast period due to the rising research activities in the complement therapeutics, well-developed healthcare infrastructure and increasing patient pool.
Some of the key players operating in the next-generation complement therapeutics market are Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB, and others.
Competitive Landscape
Some Major Key Players In The Next-Generation Complement Therapeutics Market:
- Amgen
- CSL Behring
- Innovent Biologics
- Novartis
- Regeneron
- Roche
- Sanofi
- Takeda
- UCB
- Other Prominent Players
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 6.9 Bn |
|
Revenue Forecast In 2031 |
USD 23.04 Bn |
|
Growth Rate CAGR |
CAGR of 14.39% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Target Disease Indication, Therapeutic Area, Molecule Type, Type Of Therapy, Route Of Administration |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB, and others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
